Welcome to our dedicated page for Indivior Pharmaceuticals SEC filings (Ticker: INDV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Indivior Pharmaceuticals, Inc. filings document formal disclosures for a Nasdaq-listed specialty pharmaceutical company focused on buprenorphine-based treatments for opioid use disorder. Its 8-K reports cover operating results, Regulation FD presentations, material agreements, capital-structure matters, and financing events, including the 0.625% Convertible Senior Notes due 2031.
Indivior’s proxy materials describe shareholder voting matters, board and governance practices, executive compensation, and the company’s operating roadmap for SUBLOCADE growth. The filing record also includes common-stock registration details, financial disclosures tied to its OUD treatment business, share-repurchase activity, and registration-status matters.
Indivior PLC director Keith Humphreys reported acquiring additional ordinary shares in the company. On January 5, 2026, he obtained 775 ordinary shares at a price of $35.3926 per share, increasing his direct beneficial holdings to 5,802 shares.
The shares were acquired through Humphreys’ participation in a Non-Executive Director Purchase Plan, under which a portion of his fees for serving as a director is received in stock instead of cash. This filing reflects a compensation-related share purchase rather than an open-market discretionary trade.
Indivior PLC director Daniel A. Ninivaggi reported acquiring 775 ordinary shares of the company on January 5, 2026 at a price of $35.3926 per share.
The filing shows these shares were obtained through a Non-Executive Director Purchase Plan, where a portion of his director fees is taken in stock instead of cash. Following this transaction, he beneficially owned 16,923 ordinary shares, held directly.
Indivior plc director Mark Stejbach reported acquiring 775 ordinary shares of Indivior on January 5, 2026 at a price of $35.3926 per share. Following this transaction, he beneficially owns 16,847 ordinary shares, held directly.
According to the disclosure, the shares were received through a Non-Executive Director Purchase Plan, under which a portion of his director fees is taken in stock instead of cash. This reflects compensation taken in equity rather than an open-market investment decision.
Indivior PLC director David E. Wheadon reported acquiring additional ordinary shares of the company. On 01/05/2026, he obtained 1,771 ordinary shares at a price of $35.3926 per share, bringing his directly held stake to 14,395 shares after the transaction.
According to the disclosure, these shares were acquired through his participation in a Non-Executive Director Purchase Plan, under which he receives a portion of his director fees in stock instead of cash.
Indivior PLC director reports existing share ownership. A Form 3 filing shows that director Ryan Barbara beneficially owns 1,188 ordinary shares of Indivior PLC, held directly. This filing is an initial disclosure of holdings rather than a new purchase or sale, giving investors a baseline view of this director’s equity stake in the company.
Indivior plc director Daniel A. Ninivaggi filed an initial ownership report showing beneficial ownership of 16,148 Ordinary Shares of Indivior plc. These shares are reported as held directly by the director. The filing date of the ownership event is listed as 01/01/2026, and no derivative securities are reported in the derivative securities table.
Indivior plc director Kingsley Stuart A filed an initial ownership report showing a modest personal stake in the company. As of January 1, 2026, he beneficially owned 920 ordinary shares, held directly. The filing indicates no derivative securities such as options or warrants. The document also references a power of attorney authorizing Jordan Saltzberg to sign on the reporting person's behalf.
Indivior plc director Juliet Thompson reported her initial ownership of the company’s ordinary shares. She holds 3,850 ordinary shares directly and an additional 5,775 ordinary shares indirectly through her spouse, reflecting her total beneficial stake as of the reported event date. The filing is an initial statement of beneficial ownership and does not reflect a new purchase or sale, but rather discloses Thompson’s existing holdings in connection with her role as a director.
Indivior PLC director Mark Stejbach has filed an initial beneficial ownership report showing his equity stake in the company. As of January 1, 2026, he beneficially owned 16,072 Ordinary Shares of Indivior PLC, held directly. This filing is a Form 3, which establishes his starting share position as a director and does not reflect a new purchase or sale, only his reported holdings on that date.
Indivior PLC filed an initial insider ownership report for Chief Executive Officer and director Joseph Ciaffoni. The filing shows he directly owns 56,000 ordinary shares. It also lists equity awards giving him rights to additional shares in the future.
Ciaffoni holds 1,266,903 performance stock units, each representing a contingent right to one ordinary share at an exercise price of $0. These units were granted on May 13, 2025 and may vest based on achieving specific volume weighted average price per share targets over any 30 consecutive trading days on or after May 8, 2026, with vesting tranches tied to VWAP levels from $15.00 to $35.00. He also holds 422,302 restricted stock units, granted on May 13, 2025, each convertible into one ordinary share at $0 and scheduled to vest in a single installment on May 8, 2028.